Other companies that have developed FLT3 inhibitors for AML include Cephalon (now part of Teva) - which reported disappointing data with its lestaurtinib candidate a couple of years ago ...

It's not the first time Teva has been judged to have broken European antitrust rules: in November 2020 the EU fined Teva and its neurology unit Cephalon €60.5 million for an elaborate "pay for ...

After hours: January 30 at 6:56:28 PM EST Loading Chart for HII ...